HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and raised the price target from $6 to $7.5.
August 12, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Akebia Therapeutics and raised the price target from $6 to $7.5, indicating a positive outlook.
The raised price target and maintained Buy rating from a reputable analyst firm suggest increased investor confidence and potential for stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100